RIGL
Rigel Pharmaceuticals Inc Health Care Pharmaceutical Preparations Russell 3000
$51.31Close
$939.5MMarket cap
$25.44 – $51.4552-week range
Nov 5, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 94 · stronger than 94% of stocks over 12 months
- Near its high at its 52-week high
Cautions
- Earnings shrinking EPS −73% year on year
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
102% above the low
1wk
up 6.6%
price change
1mo
up 6.6%
price change
12-month return
up 62%
market up 11% ·
its own up 64%
F-score
7 / 9
Strong
Altman Z
3.54
Low risk
P/E
2.6×
price / earnings
PEG
0.00
P/E / EPS growth
P/B
2.4×
price / book
Earnings yield
up 13.2%
EBIT / enterprise value
Cheaper than
81%
of the market · markedly cheap
Revenue growth
up 64%
year on year
EPS growth
down 73%
latest quarter · -43 pts
Sales growth
down 23%
latest quarter · -33 pts
ROE
up 186%
return on equity
Free cash margin
up 26%
$75.7M FCF
D/E
0.13
long-term debt / equity
Net debt / EBITDA
0.1×
Interest cover
—EBIT / interest
Piotroski tests
- profits not fully backed by cash
- issued more shares
- profitable on its assets
- generating cash from operations
- profitability improving
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
- assets working harder
Repair signals
- Long-term debt down 12% ($0.1B → $0.1B)
- Gross margin 89.6% → 93.3%
Trade setup
ATR%
3.2%
$1.66 a day · 2×ATR $48.00
RS
94 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
1.38
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
-
Repair to Leader in mixed conditions
- Fell 50% within the year
- 102% above the low
- Trend 8/8, above its 50-day, 200-day rising
- F-score 7/9
- Cheaper than 81%
- Altman Z 3.54 (low risk)
- Relative strength still slipping (-26 pts, 3m vs 12m)
- RS 94
Warning signs
- Shareholders diluted The share count rose 3.4% over the year, from 18m to 18m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Profit not backed by cash Reported profit of $367.0M came with $75.7M of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
Last reported
Aug 4, 2026
Results reaction
Aug 4, 2026+7% vs market2 sessions after results
Financials
- Gross 93%
- Net 125%
- Free cash 26%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $108.6M | $149.2M | $120.2M | $116.9M | $179.3M | $294.3M |
| Gross margin | 99% | 99% | 99% | 94% | 90% | 93% |
| Operating income | -$29.0M | -$12.5M | -$55.5M | -$20.5M | $24.2M | $125.5M |
| Net income | -$29.7M | -$17.9M | -$58.6M | -$25.1M | $17.5M | $367.0M |
| Net margin | -27% | -12% | -49% | -21% | 10% | 125% |
| Earnings per share | -$1.76 | -$1.05 | -$3.44 | -$1.44 | $0.99 | $19.48 |
| Free cash flow | -$53.4M | $5.3M | -$74.2M | -$5.7M | $31.5M | $75.7M |
| Free cash margin | -49% | 4% | -62% | -5% | 18% | 26% |
| Cash | $30.4M | $18.9M | $24.5M | $32.8M | $56.7M | $40.6M |
| Long-term debt | $20.0M | $20.0M | $40.0M | $60.0M | $60.0M | $52.5M |
| Shareholders' equity | $34.0M | $30.4M | -$13.6M | -$28.6M | $3.3M | $391.5M |
| Shares outstanding | 16.93m | 17.16m | 17.34m | 17.48m | 17.71m | 18.31m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Mar 4, 2025 | Annual ↗ | Dec 31, 2024 | 63d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Mar 5, 2024 | Annual ↗ | Dec 31, 2023 | 65d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 4, 2026 | Results ↗ |
| Jul 1, 2026 | Director or officer change ↗ |
| Jun 17, 2026 | Acquisition or disposal ↗ |
| May 20, 2026 | Director or officer change · Shareholder vote ↗ |
| May 12, 2026 | Material agreement ↗ |
| May 5, 2026 | Results ↗ |
| Apr 21, 2026 | Agreement ended ↗ |
| Mar 3, 2026 | Results ↗ |
| Feb 3, 2026 | Director or officer change ↗ |
| Jan 12, 2026 | Results · Other events ↗ |
| Dec 10, 2025 | Other events ↗ |
| Nov 4, 2025 | Results ↗ |